CU20170138A7 - Mycobacterium recombinante como un agente inmunoterapéutico para el tratamiento de cáncer - Google Patents

Mycobacterium recombinante como un agente inmunoterapéutico para el tratamiento de cáncer

Info

Publication number
CU20170138A7
CU20170138A7 CUP2017000138A CU20170138A CU20170138A7 CU 20170138 A7 CU20170138 A7 CU 20170138A7 CU P2017000138 A CUP2017000138 A CU P2017000138A CU 20170138 A CU20170138 A CU 20170138A CU 20170138 A7 CU20170138 A7 CU 20170138A7
Authority
CU
Cuba
Prior art keywords
immunotherapeutic agent
cancer treatment
recombinant
mycobacterium
mycobacterium recombinant
Prior art date
Application number
CUP2017000138A
Other languages
English (en)
Inventor
Leander Grode
Original Assignee
Vakzine Projekt Man Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Man Gmbh filed Critical Vakzine Projekt Man Gmbh
Publication of CU20170138A7 publication Critical patent/CU20170138A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01005—Urease (3.5.1.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La invención se relaciona con una célula de Mycobacterium recombinante para su uso como un agente inmunoterapéutico en el tratamiento de cáncer, particularmente en el tratamiento de tumores sólidos. Más particularmente, la invención se relaciona con la inmunoterapia de carcinoma de vejiga.<br />  </p>
CUP2017000138A 2015-05-04 2016-05-03 Mycobacterium recombinante como un agente inmunoterapéutico para el tratamiento de cáncer CU20170138A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166206.1A EP3090757A1 (en) 2015-05-04 2015-05-04 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US201562387407P 2015-12-23 2015-12-23
PCT/EP2016/059872 WO2016177717A1 (en) 2015-05-04 2016-05-03 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer

Publications (1)

Publication Number Publication Date
CU20170138A7 true CU20170138A7 (es) 2018-04-03

Family

ID=53054880

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000138A CU20170138A7 (es) 2015-05-04 2016-05-03 Mycobacterium recombinante como un agente inmunoterapéutico para el tratamiento de cáncer

Country Status (24)

Country Link
US (2) US10525118B2 (es)
EP (2) EP3090757A1 (es)
JP (1) JP6778697B2 (es)
KR (1) KR102667859B1 (es)
CN (1) CN107864656A (es)
AU (1) AU2016258885B2 (es)
BR (1) BR112017023747A2 (es)
CA (1) CA2984602C (es)
CU (1) CU20170138A7 (es)
CY (1) CY1123754T1 (es)
DK (1) DK3291831T3 (es)
EA (1) EA036492B1 (es)
ES (1) ES2845724T3 (es)
HR (1) HRP20210107T1 (es)
HU (1) HUE052711T2 (es)
IL (1) IL255303B (es)
LT (1) LT3291831T (es)
MX (1) MX389038B (es)
PH (1) PH12017502011A1 (es)
PL (1) PL3291831T3 (es)
PT (1) PT3291831T (es)
RS (1) RS61333B1 (es)
SI (1) SI3291831T1 (es)
WO (1) WO2016177717A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512499A (ja) * 2021-03-22 2024-03-19 クリップスビーエヌシー・カンパニー・リミテッド 新規な組換えマイコバクテリウムスメグマチス菌株およびその用途
EP4122491A1 (en) * 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
US20240277825A1 (en) * 2021-07-22 2024-08-22 Serum Life Science Europe Gmbh Recombinant Mycobacterium as an Immunotherapeutic Agent for the Second-Line Therapy of Bladder Carcinoma
IL310225A (en) * 2021-07-22 2024-03-01 Serum Life Science Europe Gmbh Recombinant MYCOBACTERIUM as an immunotherapeutic agent for the second-line treatment of bladder carcinoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733151A (en) 1996-08-23 1998-03-31 Edsall; David Electrical clamping connection device
CA2523084C (en) 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
AU2014210617B2 (en) * 2004-10-21 2016-07-21 Vakzine Projekt Management Gmbh Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
EA026661B1 (ru) * 2010-09-20 2017-05-31 Вакцине Проект Менеджмент Гмбх Вакцина и способ вакцинации против туберкулеза
PL2654783T3 (pl) * 2010-12-21 2017-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinowane Mycobacterium jako szczepionka
US9678075B2 (en) * 2011-06-10 2017-06-13 Deutsches Krebsforschungszentrum Prediction of recurrence for bladder cancer by a protein signature in tissue samples
EP2620159A1 (en) * 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria

Also Published As

Publication number Publication date
HRP20210107T1 (hr) 2021-03-19
PH12017502011A1 (en) 2018-03-26
LT3291831T (lt) 2021-02-25
CA2984602A1 (en) 2016-11-10
MX389038B (es) 2025-03-20
EP3291831B1 (en) 2020-12-30
WO2016177717A1 (en) 2016-11-10
PL3291831T3 (pl) 2021-05-31
EP3090757A1 (en) 2016-11-09
ES2845724T3 (es) 2021-07-27
IL255303B (en) 2021-08-31
MX2017014142A (es) 2018-03-15
US20180200357A1 (en) 2018-07-19
IL255303A0 (en) 2017-12-31
DK3291831T3 (da) 2021-01-18
US20200179502A1 (en) 2020-06-11
CY1123754T1 (el) 2022-05-27
JP6778697B2 (ja) 2020-11-04
BR112017023747A2 (pt) 2018-07-31
RS61333B1 (sr) 2021-02-26
CA2984602C (en) 2023-09-05
CN107864656A (zh) 2018-03-30
EA036492B1 (ru) 2020-11-17
KR20170140328A (ko) 2017-12-20
US10525118B2 (en) 2020-01-07
AU2016258885A1 (en) 2017-11-23
HK1247574A1 (en) 2018-09-28
AU2016258885B2 (en) 2021-12-09
JP2018520643A (ja) 2018-08-02
PT3291831T (pt) 2021-01-26
US11426453B2 (en) 2022-08-30
HUE052711T2 (hu) 2021-05-28
SI3291831T1 (sl) 2021-03-31
EA201792412A1 (ru) 2018-03-30
EP3291831A1 (en) 2018-03-14
KR102667859B1 (ko) 2024-05-21

Similar Documents

Publication Publication Date Title
CL2023000812A1 (es) Péptidos, combinaciones y andamiajes para uso en inmunoterapia contra el cáncer divisional de solic.2017-02448
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
PH12016502479A1 (en) Formulated receptor polypeptides and related methods
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
TW201613648A (en) Compounds and compositions for immunotherapy
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
BR112016030965A2 (pt) Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
UY35488A (es) Xantinas sustituidas y métodos para su uso
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
CY1123754T1 (el) Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου
UY35424A (es) Xantinas sustituidas y métodos para su uso
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
EA201591709A1 (ru) 5-бром-индирубины
BR112017022682A2 (pt) construções de caliqueamicina e métodos de uso
MX2017014168A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.